Please select the option that best describes you:
Would you resume biologic treatments such as TNF blockers in patients with symptomatic autoimmune conditions who are in remission from their cancers?
How about those with metastatic disease eager to maintain quality of life? Do you risk progression of disease if the TNF blocker is re-started?
Answer from: at Academic Institution
Most guidelines in rheumatology recommend use in patients who have been in remission for 5 years or more, there is data for safety for these patients. However, we do not know yet whether TNFi are safe in patients who have been NED for shorter periods and who may be at higher risk of recurrence given...
Sign in or Register to read more
Answer from: Medical Oncologist at Community Practice
Several meta analyses have been performed going back at least 10-15 years. Always depends on the severity of the patient’s condition, age and long term goals.